We partner with the media to inform the public of the global human crisis.
Latest News
-
February 19, 2019
The Lancet Publishes Phase 3 Results Demonstrating Efficacy, Safety and Tolerability of SUBLOCADE™ (Buprenorphine Extended-Release) Injection for Subcutaneous Use (CIII) in Patients with Moderate to Severe Opioid Use Disorder (OUD)... -
February 14, 2019
Presentation: Indivior FY 2018 Results Presentation (February 14) ... -
February 14, 2019
Indivior PLC FY 2018 Financial Results... -
February 12, 2019
Court of Appeals for the Federal Circuit Denies Motion to Stay Issuance of the Mandate... -
February 5, 2019
Court of Appeals for the Federal Circuit(CAFC) Denies Motion for Rehearing or Rehearing En Banc Following the CAFC’s Ruling Vacating the Preliminary Injunction Granted against Dr. Reddy’s Laboratories...
Upcoming Events
-
Thursday, February 14th
FY 2018 Results Presentation on February 14ᵗʰ >
-
November 13th
Stifel 2018 Healthcare Conference >
-
November 6th, 2018
Indivior Announces Upcoming Investor Events >
-
Thursday, November 1st
Nine Months Year-to-Date & Q3 2018 Results Webcast. >
Global Media Contacts
Email: IndiviorMediaContacts@indivior.com
Phone: +1 804-594-0836
UK Media Contacts
Tulchan Communications LLP
85 Fleet Street
London
EC4Y 1AE
Indivior@Tulchangroup.com
Phone: +44 (020) 7353 4200
EMEA, Australasia and China Financial Disclosure Reporting
Disclosure Of Payments, Donations & Joint Working
Media Kit
The Online Press Kit is designed to help media research our company for background information or follow-up stories. Please visit the links below to learn more.
About Indivior PLC – An overview of Indivior, including our worldwide locations and key products
Board of Directors – Biographies of Indivior’s Board
The Indivior PLC Pipeline – Information about the Indivior R&D efforts and progress of medicines in the pipeline